



NTCELL: A disease-modifying cell therapy for Parkinson's disease

Dr Belinda Di Bartolo
Chief Operating Officer

22 JUNE 2022

Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

LCT at a glance




Mission and Vision

Discovering, developing and commercialising novel treatments for debilitating conditions.



Diabetes: DIABECCELL

Initially developed by LCT now being further developed by Otsuka Pharmaceutical Factory in the U.S.



Parkinson's Disease: NTCELL

A disease modifying cell therapy for Parkinson's Disease

Corporate snapshot

SHARE PRICE

A\$0.008

As at 10 June 2022

MARKET CAPITALISATION

A\$10.3m

SHARES ON ISSUE

1,285m

OPTIONS


483m

CASH

A\$3.5m

As at 31 March 2022

Share distribution



Experienced Leadership

The Board



**Professor
Bernie Tuch**
Chair,
Interim CEO



**Robert
Willcocks**
Non-Executive
Director



**Professor
Carolyn Sue AM**
Non-Executive
Director



**Dr Andrew
Kelly**
Non-Executive
Director



Mark Licciardo
Company
Secretary

Management



**Dr Belinda
Di Bartolo**
COO



Daya Uka
CFO

Gap in the Market

- The only treatments for management of Parkinson's disease are drugs or medical implants to modulate the symptoms and signs of the disease
- There is currently no treatment to prevent progression of Parkinson's



A Growing Global Market

Parkinson's disease
market to reach
US\$11.5B by 2029

- Worth US\$5.7B by 2022 and US\$11.5B by 2029
- CAGR of 12.6% driven by an ageing population
- 10M people with Parkinson's disease globally; 100,000 in Australia alone

NTCELL Project



Source of tissue

Sub-Antarctic
Auckland Islands
Pigs
*Designated
Pathogen-free*



Choroid plexus


Surgical removal
of brain tissue
choroid plexus
Transported to
Sydney



Encapsulation of cell clusters



Regulatory approval from TGA



Clinical trial 50+ Parkinson's disease patients





Successful outcome Commercialisation

Results from Phase I/IIb Trials

- Phase I demonstrated safety and toxicity
- Phase II demonstrated dosage
 - Met primary efficacy clinical endpoint *Parkinsonism Related Dis 2021; 82: 128*
 - Clinically Relevant Effect: ≤ 6.45 points from baseline
 - Small numbers in each treatment group

UPDRS Part III Off (Motor Examination) 2-year follow-up



Source of Tissue

- Tissue source from designated pathogen-free (DPF) Auckland Islands pigs bred and maintained in NZeno facilities, Invercargill secured



NZeno Pig Facility

Pig tissue for human health

- NZeno's Pig Facility is managed as a Designated Pathogen Free Facility
- The pigs are tested against a selected panel of infectious agents and *designated free* of those agents by results from the American molecular diagnostics testing company, Zoologix, Inc.
- Professional and Trained Veterinary Staff
- Standard Operating Procedures for care of pigs
- Code of Conduct approved by Ministry for Primary Industries, NZ
- Oversight by Animal Ethics Committee
- Registered as Export Approved Premises by Ministry for Primary Industries, NZ



Ministry for Primary Industries
Manatū Ahu Matua




NZENO02 Sector Audit

Step: 7.1 (started on 1.1, ceiling step 7)
Issued by: Heather Henry
Phone: 0220197101
Email: heather.henry@mpi.govt.nz
Operator: NZENO02
Name: NZEno Limited - Invercargill Facility
Report ID: NZENO02SectorAudit/20220321
Outcome: Acceptable
Verification Period: 2022-03-17 to 2022-03-30
Verification Date: 2022-03-21
Published: 2022-03-21 15:09
Next Audit Due: 2023-03-30

Manufacturing

- Perfecting our manufacturing process
- NTCELL to be prepared in non-GMP facility at University of Technology, Sydney in readiness to move to a GMP facility
- Agreement with Sydney-based start-up OptiCellAI. Using digitally enhanced patented AI methods to consistently optimise capsule selection and maintenance of NTCELL



Regulatory Approval

- Regulatory approval required from Therapeutic Goods Administration (TGA)
- Likely to be the first Australian xenotransplantation trial with living cells
- Approval for two similar trials was obtained from Medsafe, the NZ equivalent of the TGA, in 2012 and 2015




Australian Government

Department of Health
Therapeutic Goods Administration


Clinical Trial and Monitoring

- Aim is to modulate disease progression. Our phase I/II trials demonstrated safety and identified effective dosages
- Planned site of clinical trial is Sydney, where state-of-the-art PET scanner is being installed. Scanner can detect changes at level of sophistication previously unavailable
- Professor Carolyn Sue (LCT Non-Executive Director) is an international authority on Parkinson's disease
- Patients recruited to the trial early to mid-stage Parkinson's disease
- Plan to recruit 50+ recipients; half will receive NTCELL via surgical implantation



NTCELL Timeline

PROPOSED PROJECT TIMELINE



Other Research and Development Initiatives

- Diabecell a potential future revenue stream via Otsuka Pharmaceutical Factory, which is seeking FDA approval for the product. LCT has 5% royalty on eventual product sales that use Immupel encapsulation technology
- Other value-adding opportunities under active consideration



Investor milestones

NTCELL: Confirmation of manufacture in non-GMP facility	Q3 2022
GMP manufacturing commences	Q4 2022
Regulatory approval for third clinical trial	Q4 2023
First implants in human trial participants	Q1 2024
Other value-adding opportunities	To be confirmed

Note: Timing expectations are based on current best estimates and may be subject to change



Investment summary

GROWING MARKET

Parkinson's disease a growing global issue.

GROUNDBREAKING RESEARCH

No treatment available to halt disease's progression.

EXPERIENCED TEAM

World-leading researchers in Parkinson's together with industry know-how.

VALUE-ADDING

Further opportunities for growth from AI, other projects.



 @lctglobal

 LCT - Living Cell Technologies

 @lctglobal

lctglobal.com